Cedars-Sinai’s IBD Drug Development and Discovery Unit (IBD3) is not a fee-for-service group. Our unit currently maintains relationships with several biotechnology and/or pharmaceutical companies to combine resources and expertise toward the development of new therapeutics in the treatment of Inflammatory Bowel Disease.

Our goal is to collaborate with industry partners in programs anywhere from early discovery to proof-of-concept (POC) trials.